Skip to main content

Galbraith Kenneth's Form 4 filing

Zymeworks Inc. (ZYME) · filed Jan 5, 2026

Accession no.
0001193125-26-003097
Filed
Jan 5, 2026
Trade date
Jan 5, 2026
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.36M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Galbraith KennethCIK 0001567045Director, Officer (Chair & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 5, 2026Common StockMOption exerciseAcquired+47,668$0.00F1$0180,943Direct
Jan 5, 2026Common StockSSaleDisposed−22,657$25.10F3−$568,690.7158,286Direct
Jan 5, 2026Common StockMOption exerciseAcquired+66,666$0.00F4$0224,952Direct
Jan 5, 2026Common StockSSaleDisposed−31,686$25.10F3−$795,318.6193,266Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 5, 2026Common StockMOption exerciseDisposed−47,668$0.00$00Direct
Jan 5, 2026Common StockMOption exerciseDisposed−66,666$0.00$066,668Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.715 to $25.84, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 2 transactions in Table I.

F4

Represents shares of common stock issued upon vesting of one third of the RSUs granted on January 5, 2024.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)